<DOC>
	<DOCNO>NCT00999518</DOCNO>
	<brief_summary>In previous study patient interstitial cystitis/ painful bladder syndrome ( IC/PBS ) , tanezumab show efficacious relieve pain associate IC/PBS , well effect reduce urinary urgency . Only one dose study , tanezumab well tolerate . In study , hypothesis test tanezumab show efficacy several dos reduce pain sufficient tolerability . Tanezumab 's safety also assess different dose level</brief_summary>
	<brief_title>A Study To Investigate Tanezumab In Patients With Interstitial Cystitis/ Painful Bladder Syndrome</brief_title>
	<detailed_description>This study terminate 16 November 2010 follow US FDA partial clinical hold tanezumab interstitial cystitis clinical study announce 19 July 2010 potential safety issue , follow pre-planned interim analysis .</detailed_description>
	<mesh_term>Cystitis</mesh_term>
	<mesh_term>Cystitis , Interstitial</mesh_term>
	<criteria>Patients interstitial cystitis/ painful bladder syndrome 6 month moderate severe pain micturition frequency great 7 per day . Patients stable oral medicine interstitial cystitis/ painful bladder syndrome least 3 month . Other therapy might need stop . Patients certain recent treatment interstitial cystitis/ painful bladder syndrome . Body mass index ( BMI ) &gt; 39 kg/m2 . History allergic anaphylactic reaction therapeutic diagnostic monoclonal antibody IgGfusion protein . Patients peripheral neuropathy . Patients Type I type II diabetes mellitus HbA1c &gt; 8.0 % .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Randomized double blind placebo-controlled parallel-group dose-range find interstitial cystitis efficacy pain urinary symptom safety</keyword>
</DOC>